Sunshine Biopharma (SBFM) EBITDA Margin (2015 - 2026)
Sunshine Biopharma (SBFM) reported EBITDA Margin of 18.81% for Q1 2026, down 585.0% on a YoY basis from 3.88% in Q1 2025, and up 14.41% quarter-over-quarter from 21.98% in Q4 2025.
Sunshine Biopharma (SBFM) EBITDA Margin (2015 - 2026) Analysis & Trends
Sunshine Biopharma has reported EBITDA Margin for 10 years, with the latest figure at 18.81% in Q1 2026.
- For the quarter ending Q1 2026, EBITDA Margin fell 585.0% year-over-year to 18.81%; the trailing twelve-month figure through Mar 2026 stood at 15.72% (up 80.0% YoY), and the FY2025 full-year result was 14.35%, up 475.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 18.81%, up from 21.98% in the prior quarter.
- The five-year high for EBITDA Margin was 4.1% in Q3 2024, with the low at 1131.07% in Q3 2022.
- Historically, EBITDA Margin has averaged 195.21% across 5 years, with a median of 18.81% in 2026.
- The largest YoY upside for EBITDA Margin was 1443842 bps in 2022 against a maximum downside of 136775 bps in 2022.
- Sunshine Biopharma's EBITDA Margin stood at 590.65% in 2022, then surged by 98 bps to 9.88% in 2023, then tumbled by 233 bps to 32.9% in 2024, then jumped by 33 bps to 21.98% in 2025, then grew by 14 bps to 18.81% in 2026.
- The last three EBITDA Margin figures came in at 18.81% (Q1 2026), 21.98% (Q4 2025), and 15.77% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 16.37% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 36.83% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 41.69% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | -1.01% |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 22.74% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 22.39% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -170.35% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -16.25% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 21.55% |
| 10 | Sunshine Biopharma | 10.94 Mn | 4.03 Mn | 2.18 Mn | -18.81% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.81% |
| Dec 31, 2025 | -21.98% |
| Sep 30, 2025 | -15.77% |
| Jun 30, 2025 | -7.29% |
| Mar 31, 2025 | -12.96% |
| Dec 31, 2024 | -32.90% |
| Sep 30, 2024 | -4.10% |
| Jun 30, 2024 | -14.29% |
| Mar 31, 2024 | -24.23% |
| Dec 31, 2023 | -9.88% |
| Sep 30, 2023 | -18.66% |
| Jun 30, 2023 | -7.37% |
| Mar 31, 2023 | -34.56% |
| Dec 31, 2022 | -590.65% |
| Sep 30, 2022 | -1,131.07% |
| Jun 30, 2022 | -366.93% |
| Mar 31, 2022 | -1,007.16% |
| Dec 31, 2021 | 777.10% |
| Sep 30, 2021 | -8,030.06% |
| Jun 30, 2021 | -5,457.80% |